1
David M Goldenberg: Immunotherapy of B-cell malignancies using anti-CD22 antibodies. Immunomedics, Foley & Lardner, October 23, 2001: US06306393 (244 worldwide citation)

B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, includin ...


2
David M Goldenberg: Immunotherapy of B-cell malignancies using anti-CD22 antibodies. Immunomedics, Foley & Lardner, February 6, 2001: US06183744 (137 worldwide citation)

B-Cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, includin ...


3
David M Goldenberg: Intraperative, intravascular and endoscopic tumor and lesion detection and therapy with monovalent antibody fragments. Immunomedics, Foley & Lardner, February 10, 1998: US05716595 (130 worldwide citation)

Methods are provided for close-range intraoperative, endoscopic and intravascular detection and treatment of lesions, including tumors and non-malignant lesions. The methods use agents labeled with isotopic and non-isotopic agents. Also provided are methods for detection and treatment of lesions wit ...


4
Hans Hansen, Zhengxing Qu, David M Goldenberg: Anti-CD20 antibodies and fusion proteins thereof and methods of use. Immunomedics, Rossi Kimms & McDowell, December 19, 2006: US07151164 (106 worldwide citation)

The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and ...


5
David M Goldenberg: Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells. Immunomedics, Foley & Lardner, November 25, 2003: US06653104 (103 worldwide citation)

The present invention relates to immunotoxins that effectively kill malignant cells having a given marker. The immunotoxins are reagents that comprise internalizing antibodies conjugated to cytotoxic ribonucleases or fragments thereof. The internalizing antibodies are capable of binding with a chose ...


6
Hans J Hansen, Shui on Leung, Zhengxing Qu, David M Goldenberg: Internalizing anti-CD74 antibodies and methods of use. Immunomedics, Faegre & Benson, Richard A Nakashima, December 25, 2007: US07312318 (89 worldwide citation)

The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B ...


7
Chien Hsing Chang, David M Goldenberg, William J McBride, Edmund A Rossi: Stably tethered structures of defined compositions with multiple functions or binding specificities. IBC Pharmaceuticals, Richard A Nakashima, April 21, 2009: US07521056 (73 worldwide citation)

The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization an ...


8
David M Goldenberg: Detection and therapy of lesions with biotin/avidin conjugates. Immunomedics, Foley & Lardner, June 11, 1996: US05525338 (73 worldwide citation)

Methods are provided for detecting and/or treating lesions in a patient. The methods use a targeting composition comprised of a biotin and targeting protein conjugate or an avidin and targeting protein conjugate; optionally, a clearing composition comprised of avidin, when the targeting composition ...


9
Chien Hsing Chang, David M Goldenberg, William J McBride, Edmund A Rossi: Methods and compositions for generating bioactive assemblies of increased complexity and uses. IBC Pharmaceuticals, Richard A Nakashima, May 19, 2009: US07534866 (72 worldwide citation)

The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which ta ...


10
Chien Hsing Chang, David M Goldenberg, Edmund A Rossi: Multivalent immunoglobulin-based bioactive assemblies. IBC Pharmaceuticals, Richard A Nakashima, May 5, 2009: US07527787 (71 worldwide citation)

The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and w ...